Tower Research Capital LLC (Trc) Vaxcyte, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $3.68 Billion
- Q3 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 978 shares of PCVX stock, worth $84,626. This represents 0.0% of its overall portfolio holdings.
Number of Shares
978
Previous 23,535
95.84%
Holding current value
$84,626
Previous $1.78 Million
93.75%
% of portfolio
0.0%
Previous 0.03%
Shares
17 transactions
Others Institutions Holding PCVX
# of Institutions
353Shares Held
122MCall Options Held
775KPut Options Held
433K-
Vanguard Group Inc Valley Forge, PA11.4MShares$990 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X010.9MShares$945 Million0.67% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$860 Million0.02% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.69MShares$752 Million13.83% of portfolio
-
Capital Research Global Investors Los Angeles, CA4.9MShares$424 Million0.12% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $5.13B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...